Skip to main
CLPT
CLPT logo

CLPT Stock Forecast & Price Target

CLPT Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

ClearPoint Neuro Inc is positioned for a positive financial outlook due to its anticipated 20% revenue growth in 2024 driven by the expansion of its partnership base and enhanced service offerings in the Biologics sector. The company closed 2023 with a commendable 17% topline growth and significantly reduced cash burn, indicating improved operational efficiency and profitability. Additionally, ClearPoint has gained momentum in 2024 with key product approvals and record system installations, reinforcing its competitive standing in the market for minimally invasive surgical procedures.

Bears say

ClearPoint Neuro Inc has demonstrated a significant decrease in cash burn, reducing it from $5.8 million in Q1 2023 to $1.2 million in Q4 2023, which reflects improved cash management. Despite this trend, the continued reliance on cash reserves indicates potential liquidity concerns, especially considering the need for ongoing investments in product development and market expansion. Furthermore, while the company expects to maintain this trend in cash burn reduction, the underlying financial health may still be vulnerable due to ongoing operational costs and the competitive landscape in the medical device industry.

CLPT has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Clearpoint Neuro Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Clearpoint Neuro Inc (CLPT) Forecast

Analysts have given CLPT a Strong Buy based on their latest research and market trends.

According to 3 analysts, CLPT has a Strong Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $27.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $27.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Clearpoint Neuro Inc (CLPT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.